First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset

Mostrar otras versiones (1)

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death‐ligand 1 (PD‐L1) tumor proportion score of 50% or greater...

Descripción completa

Detalles Bibliográficos
Autores principales: Satouchi, Miyako, Nosaki, Kaname, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Aoe, Keisuke, Kurata, Takayasu, Sekine, Akimasa, Horiike, Atsushi, Fukuhara, Tatsuro, Sugawara, Shunichi, Umemura, Shigeki, Saka, Hideo, Okamoto, Isamu, Yamamoto, Nobuyuki, Sakai, Hiroshi, Kishi, Kazuma, Katakami, Nobuyuki, Horinouchi, Hidehito, Hida, Toyoaki, Okamoto, Hiroaki, Atagi, Shinji, Ohira, Tatsuo, Rong Han, Shi, Noguchi, Kazuo, Ebiana, Victoria, Hotta, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645705/
https://www.ncbi.nlm.nih.gov/pubmed/34543477
http://dx.doi.org/10.1111/cas.15144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645705/
https://www.ncbi.nlm.nih.gov/pubmed/34543477
http://dx.doi.org/10.1111/cas.15144

Ejemplares similares